Kiyan, Hulya TubaUvez, AycaErkisa, MerveIkitimur-Armutak, Elif IlkayYilmazer, NadimEsener, Osman Behzat BurakKutucu, Deniz Erol2024-05-192024-05-1920231570-18081875-628Xhttps://doi.org10.2174/1570180820666230110155332https://hdl.handle.net/20.500.12713/5508Introduction Angiogenesis is involved in many physiological and pathological conditions including cancer. A number of TRP channels induce angiogenesis, promote cell proliferation or induce apoptosis in several types of human cancers. Therefore, TRP channels may be considered potential pharmacological targets for therapeutic options of disorders caused by insufficient angiogenesis or aberrant vascularization. Aims This study aimed to comparatively investigate in vitro anti-cancer and in vivo anti-angiogenic effects of TRPC blockers Pyr-3 and SKF-96365. Methods For anti-cancer effects, four cancer cell lines (MDA-MB-231, A549, PC-3, and HCT-116) were used. In vivo anti-angiogenic effects were investigated by employing in vivo CAM assay of fertilized hen eggs. Results Pyr-3 affected cell viability in a dose-dependent manner, all concentrations of SKF-96365 significantly reduced cell viability in all cell lines. Pyr-3 and SKF-96365 at concentrations of 2.5 & mu;g/pellet and 50 & mu;g/pellet, respectively inhibited in vivo angiogenesis significantly. Conclusion The concentration of 2.5 & mu;g/pellet caused no irritation, whereas 50 & mu;g/pellet produced some slight irritation. Apart from their anti-cancer effects, our findings indicate that Pyr-3 and SKF-96365 may be promising anti-angiogenic agents for the treatment of angiogenesis-related disorders.eninfo:eu-repo/semantics/openAccessPyr-3Skf-96365CancerAngiogenesisIn Vivo Cam AssayCorpus Luteum FormationArticle207957964WOS:0010183551000152-s2.0-85159792279N/A10.2174/1570180820666230110155332Q3